← Back to Search

Dietary Supplement

Nitric Oxide Supplement for Prehypertension

Phase 1 & 2

Waitlist Available

Led By Ernst Schwarz, MD, PhD

Research Sponsored by Neogenis Laboratories

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30 days

Awards & highlights

Study Summary

This trial found that taking Neo40, a nitrate supplement in the form of a lozenge, will reduce blood pressure in adults who have prehypertension.

Who is the study for?

This trial is for adults aged 18-80 with prehypertension, which means their blood pressure readings are at or above 135/80 mmHg. Participants must be able to give informed consent and follow the study's procedures. Those with serious internal or heart diseases, using blood pressure meds, or unable to consent are excluded.Check my eligibility

What is being tested?

The study tests if Neo40(TM), a nitric oxide supplement taken orally as a lozenge, can lower blood pressure in prehypertensive adults compared to a placebo (a dummy pill).See study design

What are the potential side effects?

Potential side effects of the nitric oxide supplement may include headaches, dizziness due to low blood pressure, possible stomach upset or changes in heart rate. Placebo effects should have no active side effects but can cause similar symptoms due to psychological factors.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Reduction in Systolic and Diastolic Blood Pressure Readings

Secondary outcome measures

Improvement in Functional Capacity

Other outcome measures

Improvement in Quality of Life

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Nitric Oxide supplementActive Control1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Neogenis LaboratoriesLead Sponsor

5 Previous Clinical Trials

164 Total Patients Enrolled

2 Trials studying Hypertension

109 Patients Enrolled for Hypertension

Ernst Schwarz, MD, PhDPrincipal InvestigatorCalifornia Medical Institute, Cedars Sinai Medical Center

1 Previous Clinical Trials

Media Library

Nitric Oxide supplement (Dietary Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT01937754 — Phase 1 & 2

Hypertension Research Study Groups: Placebo, Nitric Oxide supplement

Hypertension Clinical Trial 2023: Nitric Oxide supplement Highlights & Side Effects. Trial Name: NCT01937754 — Phase 1 & 2

Nitric Oxide supplement (Dietary Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01937754 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it possible to register for the clinical experiment?

"To be considered for this drug trial, applicants must have prehypertension and range in age from 18 to 80 years. The research team is looking to recruit around 30 qualified participants."

Answered by AI

Are there currently any openings for participants in this medical trial?

"The records maintained on clinicaltrials.gov reveal that enrollment for this trial is not presently open, having been first posted in January 2013 and last updated four months later. However, there are 16 other studies actively recruiting new members at the present time."

Answered by AI